Skip to main navigation

Jump to navigation

About
Focus
Products
- ALLN-177
- ALLN-346
- Pipeline
- FAQs
Investors
Careers
Contact

Home ›
Investors

In the News

In the News

June 5, 2019

Source

Endpoints News

Mid-stage data on Allena's hyperoxaluria drug fuel optimism ahead of pivotal readout

March 29, 2019

Source

Drug Development Technology

Allena Pharmaceuticals and DCRI to support trial of reloxaliase

March 1, 2019

Source

Asia-Pacific Biotech News

Renal complications of oxalate disorders

February 22, 2019

Source

Urology Times

FDA alignment reached on phase III trial of hyperoxaluria therapy

January 4, 2019

Source

Xconomy

Allena Promotes Brenner to CEO, Margolin Becomes Board Chair

January 2, 2019

Source

RARE Daily

Allena Pharmaceuticals Says It Has Finalized Design with FDA for Pivotal Trial in Hyperoxaluria Using Novel Endpoint

January 2, 2019

Source

Seeking Alpha

Allena Pharmaceuticals aligns with FDA on phase 3 program and accelerated approval pathway for reloxaliase in enteric hyperoxaluria

January 2, 2019

Source

Drug Development & Delivery

Allena Pharmaceuticals Achieves Alignment With FDA on Phase 3 Program

January 2, 2019

Source

Dow Jones Newswires

Allena Pharma's Stock Rises on Reloxaliase Positive News -- Market Mover

January 2, 2019

Source

Uro Today

Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria

Pagination

Current page 1
Page 2
Next page
Last page

Investor Relations

Overview
News Releases
In the News
Events and Presentations
Stock Information
Analyst Coverage
Corporate Governance
SEC Filings
Shareholder Services

LinkedIn
LinkedIn

Privacy Policy
Terms of Use
Social Media Community Guidelines

©2020 Allena Pharmaceuticals, Inc. All rights reserved.